Pharmacy Practice Residency, Valley Health Systems – Wincester, VA 2009-2010 Cardiology Specialty Residency, UMass Memorial Medical Center – Worcester, MA 2010-2011 Pharm.D., University of Connecticut, 2009 B.S., Pharmaceutical Studies, University of Connecticut, 2007

Anticoagulation Antiplatelet Therapy Cardiology

Vandiver, JW, Ritz, LI, Lalama, JT (2016). Chemical prophylaxis to prevent venous thromboembolism in morbid obesity: literature review and dosing recommendations. Journal Thrombolysis. 41(3):475-481. Lalama JT, Feeney ME, Vandiver JW, Beavers KD, Walter LN, McClintic JR. Assessing an enoxaparin dosing protocol in morbidly obese patients. J Thromb Thrombolysis. 2014 [DOI# 10.1007/s11239-014-1117-y]. Lalama J. Arrhythmias. In: Attridge RL, Miller ML, Moote R, Ryan L, eds. Internal Medicine: A Guide to Clinical Therapeutics. 1st ed. New York, NY: McGraw-Hill; 2013:25. Nelson, A., Lalama, J. Intermediate-Risk Pulmonary Embolism and Fibrinolysis: For Better or For Worse?. In: Linn WD. eds. Topics in Evidence-Based Pharmacy Practice. New York, NY: McGraw-Hill; 2013. http://accesspharmacy.mhmedical.com.dml.regis.edu/updatesContent.aspx?bookid=533&Sectionid=56747651. Accessed October 06, 2014. Lalama, J.T., Feeney, M.E., Vandiver JW, Beavers KD, Walter LN, McClintic JR. Assessing an enoxaparin dosing protocol in morbidly obese patients. J Thromb Thrombolysis. 2014 [DOI# 10.1007/s11239-014-1117-y]. Khan, S., Lalama, J. "What Is The CHANCE That Dual Antiplatelet Therapy Is Effective for Secondary Stroke Prevention?" (update). In: Linn WD, Al-Qadheeb N, Al-Qadheeb N, Havrda D, eds. Topics in Evidence-Based Pharmacy Practice. New York: McGraw-Hill; 2013. http://www.accesspharmacy.com/content.aspx?aID=4000318. Accessed December 2, 2013. Feeney, M., Lalama, J. "Can Newer Anticoagulants AMPLIFY the Initial Treatment of VTE?" (update). In: Linn WD, Al-Qadheeb N, Havrda D, Al-Qadheeb N, Havrda D, eds. Topics in Evidence-Based Pharmacy Practice. New York: McGraw-Hill; 2013. http://www.accesspharmacy.com/content.aspx?aID=4000312. Accessed October 27, 2013 Lalama, J. (2013). Can Newer Anticoagulants AMPLIFY the Initial Treatment of VTE? Topics in Evidence-Based Pharmacy PracticeRetrieved from http://accesspharmacy.mhmedical.com/updatesContent.aspx?bookid=533&Sectionid=45242482 Lalama, J. (2012a). Using Aspirin for Primary Prevention of Vascular and Non-Vascular Outcomes: What Are the Data? Topics in Evidence-Based Pharmacy Practice. Lalama, J. (2012b). Risk of Acute Coronary Events and Dabigatran. Topics in Evidence-Based Pharmacy Practice. Lalama, J., Lewis, P. M., Gore, J., Tran, M.T. & Donovan, J. (2012). How one academic medical center has managed potency changes with unfractionated heparin. Journal of thrombosis and thrombolysis, 1–5. Khan, S., Lalama, J. Can A Fish A Day Keep the ED Away?. In: Linn WD. eds.Topics in Evidence-Based Pharmacy Practice. New York, NY: McGraw-Hill; 2013. http://accesspharmacy.mhmedical.com/updatesContent.aspx?bookid=533&Sectionid=41703424. Accessed April 28, 2014. Lalama, J. (2012). "Dronedarone: Where To Go from Here?" In W.D. Linn, N. Al-Qadheeb, D. Havrda, N. Al-Qadheeb, D. Havrda (Eds), Topics in Evidence-Based Pharmacy Practice. http://www.accesspharmacy.com/content.aspx?aID=4000121. AccessPharmacy. Lalama, J. (2012). "Rivaroxaban: Warfarin's Newest Competitor for Non-Valvular Atrial Fibrillation" (update). In W.D. Linn, N. Al-Qadheeb, D. Havrda, N. Al-Qadheeb, D. Havrda (Eds), Topics in Evidence-Based Pharmacy Practice. http://www.accesspharmacy.com/content.aspx?aID=4000122. AccessPharmacy. Lalama, J., Brackbill, M. (2011) Characterization and Evaluation of Clopidogrel Response Testing in a Community Hospital Setting. J Clinic Experiment Cardiol 2:155. doi:10.4172/2155-9880.1000155.